Johnson & Johnson (NYSE:JNJ) Trading Up 0.4% – Here’s What Happened

Shares of Johnson & Johnson (NYSE:JNJ) rose 0.4% during mid-day trading on Monday . The stock traded as high as $154.83 and last traded at $154.91. Approximately 2,406,487 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 7,879,246 shares. The stock had previously closed at $154.22.

Wall Street Analyst Weigh In

JNJ has been the topic of several research reports. Bank of America dropped their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Finally, Stifel Nicolaus dropped their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $171.82.

Johnson & Johnson Stock Performance

The business’s fifty day simple moving average is $157.89 and its 200-day simple moving average is $154.23. The company has a market capitalization of $370.24 billion, a P/E ratio of 23.14, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.38%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s payout ratio is 57.84%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00% decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors have recently bought and sold shares of the company. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $33,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.